Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Morinda officinalis polysaccharides (MOPs) are bioactive carbohydrate polymers extracted from the roots of *Morinda officinalis* How, a traditional Chinese medicinal plant known as Ba-Ji-Tian. These polysaccharides consist of complex structural forms, including inulin-type fructans and acidic polysaccharides composed of galacturonic acid, arabinose, and galactose. MOPs demonstrate a wide range of pharmacological activities, including anti-osteoporotic, anti-inflammatory, antioxidant, and renoprotective effects. Their mechanism of action involves the modulation of the Gut-Kidney axis, where they reshape gut microbiota communities and activate PPARγ and GPCR signaling pathways to reduce systemic inflammation and renal fibrosis. Additionally, MOPs influence the BMP/Smads and Wnt/β-catenin signaling pathways to promote osteoblast differentiation and bone formation. They are being investigated for the treatment of chronic kidney disease (CKD), osteoporosis, rheumatoid arthritis, depression, and infertility.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on morinda officinalis polysaccharides.